CHOLETEC (mebrofenin) by Bracco is clinical pharmacology mebrofenin is an iminodiacetic acid (hida) derivative with no known pharmacologic action at the recommended doses. First approved in 1987.
Drug data last refreshed 20h ago · AI intelligence enriched 2w ago
CHOLETEC (Mebrofenin) is a Technetium Tc 99m–labeled hepatobiliary imaging agent used for diagnostic hepatobiliary scintigraphy. It contains no intrinsic pharmacologic activity and functions as a diagnostic tracer to visualize liver, biliary duct, gallbladder, and intestinal function. The agent is rapidly cleared from circulation via the hepatobiliary system, enabling clinicians to assess hepatic function and detect biliary obstruction or cholecystitis.
Product is in late-stage market maturity with moderate competitive pressure (30/100), signaling potential team consolidation or strategic repositioning.
CLINICAL PHARMACOLOGY Mebrofenin is an iminodiacetic acid (HIDA) derivative with no known pharmacologic action at the recommended doses. Following intravenous administration in normal subjects, Technetium Tc 99m Mebrofenin was rapidly cleared from the circulation. The mean percent injected dose…
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Worked on CHOLETEC at Bracco? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
CHOLETEC offers limited career growth given its mature, non-expanding market position and approaching loss of exclusivity. Roles are primarily focused on maintaining market share, managing pricing pressure, and optimizing distribution rather than driving innovation or expanding indications.